10x Genomics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
10x Genomics' 2024 revenue slightly decreased by 1% year-over-year, accompanied by a reduced net loss, as the company navigated strategic changes and ongoing intellectual property litigation.
NASDAQ
10x Genomics, a life sciences technology company, announced a 20% year-over-year revenue increase to $618.7 million for 2023, while also reporting a net loss of $255.1 million.